Bio-Bridge Science, Inc. Signs a Contract with JR Scientific to Form a Cell-Culture Medium Joint Venture in Beijing, China

OAK BROOK, Ill.--(BUSINESS WIRE)--Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that its wholly-owned subsidiary, Bio-Bridge Science (HK) Co., Ltd. has entered into a joint venture contract with JR Scientific Inc., a Woodland, California based manufacturer of classical and custom cell culture medium and sera products (“JRS”) and several other investors, to form a new cell culture medium joint venture in Beijing, China. The registered capital of the new joint venture will be RMB 10,000,000 (approximately US $1,464,000). Bio-Bridge Science will invest RMB 5,100,000 in cash for a 51% controlling interest and JRS will provide technology for a 15% ownership interest in the new joint venture.